For example, SGM-101, a 700 nm-conjugated mAb targeting carcinoembryonic antigen (CEA), a glycoprotein overexpressed in more than 90% of pancreatic cancers before and after neoadjuvant therapy, has been shown to allow visualization of pancreatic tumors during surgery [85,86,87]. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.